Coleman Robert E
Cancer Research Centre,Academic Unit of Clinical Oncology, Broomcross Building, Weston Park Hospital, Sheffield S10 2SJ, UK.
Cancer Treat Rev. 2006;32 Suppl 1:27-8. doi: 10.1016/s0305-7372(06)80007-1.
Bone metastases occur frequently in patients with multiple myeloma and breast, prostate, and lung cancer. Presence of metastatic bone disease (MBD) is correlated with abnormal bone remodelling, as high levels of biochemical markers of bone turnover can be detected in serum or urine from patients with these malignancies. The idea of using bone markers in the diagnosis and follow-up of patients with MBD is undergoing validation and gaining acceptance. In this conclusion, we summarise data from leading studies relating to the search for useful markers of bone resorption and bone formation in MBD.
骨转移在多发性骨髓瘤以及乳腺癌、前列腺癌和肺癌患者中很常见。转移性骨病（MBD）的存在与骨重塑异常相关，因为在这些恶性肿瘤患者的血清或尿液中可检测到高水平的骨转换生化标志物。在MBD患者的诊断和随访中使用骨标志物的想法正在接受验证并逐渐得到认可。在本综述中，我们总结了来自主要研究的数据，这些研究涉及寻找MBD中有用的骨吸收和骨形成标志物。
